Thomas de Vlaam
Private Equity Investor bei Pillar Co Management LLC
Profil
Mr. Thomas de Vlaam is a Partner at Pillar Co Management LLC.
Mr. de Vlaam was previously employed as a Founder & CEO by Amylon Therapeutics BV.
He received his undergraduate degree from the University of Groningen.
Aktive Positionen von Thomas de Vlaam
| Unternehmen | Position | Beginn |
|---|---|---|
Pillar Co Management LLC
 Pillar Co Management LLC Investment ManagersFinance Pillar Co Management LLC (Pillar VC) is a venture capital firm founded in 2016 by Jamie Goldstein. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01.07.2022 |
Ehemalige bekannte Positionen von Thomas de Vlaam
| Unternehmen | Position | Ende |
|---|---|---|
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Vorstandsvorsitzender | 31.05.2022 |
Ausbildung von Thomas de Vlaam
| University of Groningen | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Pillar Co Management LLC
Pillar Co Management LLC Investment ManagersFinance Pillar Co Management LLC (Pillar VC) is a venture capital firm founded in 2016 by Jamie Goldstein. The firm is headquartered in Boston, Massachusetts. | Finance |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |
